Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP.
BACKGROUND
We assessed the prognostic significance of pretreatment C-reactive protein (CRP) concentration in diffuse large B-cell lymphoma (DLBCL) patients.


METHODS
We retrospectively reviewed 156 patients with newly diagnosed DLBCL. Receiver operating characteristic (ROC) curve analysis was used to generate a cutoff value for CRP. Both log-rank test and multivariable analysis by Cox regression model were used to assess the impact of pretreatment CRP concentrations on the overall survival (OS) and progression-free survival (PFS).


RESULTS
Among those 156 patients enrolled, increased CRP concentration was seen in 51 patients before treatment (≥20mg/l), while the other 105 patients were considered with low CRP concentration. There was no obvious difference in the baseline characteristics between two groups. Increased CRP concentration was significantly associated with poorer OS and PFS than those patients with low CRP concentration (P=0.001 and P=0.000, respectively). Multivariable analysis further showed that CRP concentration was an independent predictor of OS (hazard ratio [HR]=0.47; 95% confidence interval [CI]=0.24-0.92, P=0.028) and PFS (HR=0.37; 95% CI=0.30-0.87, P=0.013).


CONCLUSION
CRP concentration before treatment was an independent prognostic factor in patients with DLBCL.
['Wang|Jing|J|', 'Zhou|Min|M|', 'Wang|Xiaoyue|X|', 'Xu|Jingyan|J|', 'Chen|Bing|B|', 'Ouyang|Jian|J|']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D002097:C-Reactive Protein D005260:Female D006801:Humans D016403:Lymphoma, Large B-Cell, Diffuse D008297:Male D008875:Middle Aged D012372:ROC Curve D012189:Retrospective Studies D000069283:Rituximab D016019:Survival Analysis D055815:Young Adult
C-reactive protein Diffuse large B-cell lymphoma Prognosis Rituximab